CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2, 2021—Diazyme Laboratories obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test, a high-throughput chemiluminescent immunoassay.
The test measures the subset of neutralizing antibodies that block the interaction between the receptor binding of the viral spike glycoprotein and the human ACE2 cell surface receptor. “The Diazyme neutralizing antibody test gives the scientific community and health authorities a valuable tool to evaluate the level of effective antibodies generated after infection or vaccination, and to assess adaptive immunity in studies going forward,” Chong Yuan, PhD, managing director of Diazyme, said in a press release.
Pages: 1 2